Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy?

Diabetologia

Volumn 51, Issue 9, 2008, Pages 1570-1573

  Sang, D N ^a,b,c   D'Amore, P A ^a,b  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

Author keywords

Anti VEGF; Bevacizumab; Diabetic macular oedema; Diabetic retinopathy; Macular oedema; Neovascularisation; Pegaptanib; Proliferative diabetic retinopathy; Ranibizumab; VEGF

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

BLOOD VESSEL PERMEABILITY; CELL SURVIVAL; CHOROID CAPILLARY LAYER; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; HYPERTENSION; ISCHEMIA; LASER COAGULATION; NOTE; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RETINA DETACHMENT; RETINA EDEMA; RETINA GANGLION CELL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; HUMANS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 49249129275     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-008-1078-9     Document Type: Note

References (36)

1. J Kinyoun F Barton M Fisher L Hubbard L Aiello F Ferris 3rd 1989 Detection of diabetic macular edema. Ophthalmoscopy versus photography-Early Treatment Diabetic Retinopathy Study report number 5. The ETDRS Research Group Ophthalmology 96 746 750
2. Early Treatment Diabetic Retinopathy Study Research Group 1991 Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7 Ophthalmology 98 741 756
3. Simó R, Hernández C (2008) Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia doi 10.1007/s00125-008-0989-9
4. PJ Rosenfeld DM Brown JS Heier 2006 Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419 1431
5. DM Brown CD Regillo 2007 Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients Am J Ophthalmol 144 627 637
6. JW Miller AP Adamis DT Shima 1994 Vascular permeability factor/vascular endothelial cell growth factor is temporally and spatially correlated with ocular angiogenesis in a primate model Am J Pathol 145 574 584
7. LP Aiello RL Avery PG Arrigg 1994 Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other ocular disorders N Engl J Med 331 1480 1487
8. RL Avery 2006 Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment Retina 26 352 354
9. MJ Tolentino JW Miller ES Gragoudas K Chatzistefanou N Ferrara AP Adamis 1996 Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate Arch Ophthalmol 114 964 970
10. LP Aiello SE Bursell A Clermont 1997 Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor Diabetes 46 1473 1480
11. ET Cunningham Jr AP Adamis M Altaweel 2005 A Phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema Ophthalmology 112 1747 1757
12. QD Nguyen S Tatlipinar SM Shah 2006 Vascular endothelial growth factor is a critical stimulus for diabetic macular edema Am J Ophthalmol 142 961 969
13. DW Chun JS Heier TM Topping JS Duker JM Bankert 2006 A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema Ophthalmology 113 1706 1712
14. JF Arevalo J Fromow-Guerra H Quiroz-Mercado 2007 Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up Ophthalmology 114 743 750
15. C Haritoglou D Kook A Neubauer 2006 Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema Retina 26 999 1005
16. M Shimura T Nakazawa K Yasuda 2008 Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema Am J Ophthalmol 145 854 861
17. SM Weis DA Cheresh 2005 Pathophysiological consequences of VEGF-induced vascular permeability Nature 437 497 504
18. ME Schneck L Shupenko AJ Adams 2008 The fast oscillation of the EOG in diabetes with and without mild retinopathy Doc Ophthalmol 116 231 236
19. AS Maharaj M Saint-Geniez AE Maldonado PA DAmore 2006 Vascular endothelial growth factor localization in the adult Am J Pathol 168 639 648
20. PA D'Amore 2007 Vascular endothelial cell growth factor-A: not just for endothelial cells anymore Am J Pathol 171 14 18
21. I Zachary 2005 Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential Neurosignals 14 207 221
22. U Kilic E Kilic A Jarve 2006 Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways J Neurosci 26 12439 12446
23. K Nishijima Y-S Ng L Zhong 2007 VEGF-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury Am J Path 171 53 67
24. M Saint-Geniez PA D'Amore 2004 Development and pathology of the hyaloid, choroidal and retinal vasculature Int J Dev Biol 48 1045 1058
25. T Kamba BY Tam H Hashizume 2006 VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature Am J Physiol Heart Circ Physiol 290 H560 H576
26. AS Maharaj TE Walshe M Saint-Geniez 2008 VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma J Exp Med 205 491 501
27. S Peters P Heiduschka S Julien 2007 Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab Am J Ophthalmol 143 995 1002
28. AS Maharaj M Saint-Geniez TE Walshe 2008 VEGF is required for neuroretina survival and function Invest Ophthalmol Vis Sci 49 E 5836
29. UU Inan B Avci T Kusbeci B Kaderli R Avci SG Temel 2007 Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes Invest Ophthalmol Vis Sci 48 1773 1781
30. M Saint-Geniez AE Maldonado PA D'Amore 2006 VEGF expression and receptor activation in the choroid during development and in the adult Invest Ophthalmol Vis Sci 47 3135 3142
31. PJ Rosenfeld DM Brown JS Heier 2006 Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419 1431
32. DM Brown PK Kaiser M Michels 2006 Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 1432 1444
33. P van Wijngaarden DJ Coster KA Williams 2005 Inhibitors of ocular neovascularization: promises and potential problems JAMA 293 1509 1513
34. H Hurwitz L Fehrenbacher W Novotny 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342
35. B Yang DF Cross M Ollerenshaw BA Millward AG Demaine 2003 Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus J Diabetes Complications 17 1 6
36. M Buraczynska P Ksiazek I Baranowicz-Gaszczyk L Jozwiak 2007 Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients Nephrol Dial Transplant 22 827 832